Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection
Joo-Yun Byun, Yi T Koh, Sun Young Jang, Jennifer W Witcher, Jason R Chan, Anna Pustilnik, Mark J Daniels, Young Hoon Kim, Kwee Hyun Suh, Matthew D Linnik, Young-Mi Lee, Joo-Yun Byun, Yi T Koh, Sun Young Jang, Jennifer W Witcher, Jason R Chan, Anna Pustilnik, Mark J Daniels, Young Hoon Kim, Kwee Hyun Suh, Matthew D Linnik, Young-Mi Lee
Abstract
The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Park et al. Arthritis Res. Ther. 18, 91, https://doi.org/10.1186/s13075-016-0988-z , 2016). This study describes the translation of nonclinical research studies to a phase I clinical trial in healthy volunteers in which pharmacokinetics (PKs) and pharmacodynamics (PDs) were evaluated for dose determination. The BTK protein kinase inhibitory effects of poseltinib in human peripheral blood mononuclear cells (PBMCs) and in rats with collagen-induced arthritis (CIA) were evaluated. High-dimensional phosphorylation analysis was conducted on human immune cells such as B cells, CD8 + memory cells, CD4 + memory cells, NK cells, neutrophils, and monocytes, to map the impact of poseltinib on BTK/PLC and AKT signaling pathways. PK and PD profiles were evaluated in a first-in-human study in healthy donors, and a PK/PD model was established based on BTK occupancy. Poseltinib bound to the BTK protein and modulated BTK phosphorylation in human PBMCs. High-dimensional phosphorylation analysis of 94 nodes showed that poseltinib had the highest impact on anti-IgM + CD40L stimulated B cells, however, lower impacts on anti-CD3/CD-28 stimulated T cells, IL-2 stimulated CD4 + T cells and NK cells, M-CSF stimulated monocytes, or LPS-induced granulocytes. In anti-IgM + CD40L stimulated B cells, poseltinib inhibited the phosphorylation of BTK, AKT, and PLCγ2. Moreover, poseltinib dose dependently improved arthritis disease severity in CIA rat model. In a clinical phase I trial for healthy volunteers, poseltinib exhibited dose-dependent and persistent BTK occupancy in PBMCs of all poseltinib-administrated patients in the study. More than 80% of BTK occupancy at 40 mg dosing was maintained for up to 48 h after the first dose. A first-in-human healthy volunteer study of poseltinib established target engagement with circulating BTK protein. Desirable PK and PD properties were observed, and a modeling approach was used for rational dose selection for subsequent trials. Poseltinib was confirmed as a potential BTK inhibitor for the treatment of autoimmune diseases.Trial registration: This article includes the results of a clinical intervention on human participants [NCT01765478].
Conflict of interest statement
The authors declare no competing interests.
© 2021. The Author(s).
Figures
References
- Park JK, et al. HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: A potential drug for rheumatoid arthritis. Arthritis Res. Ther. 2016;18:91. doi: 10.1186/s13075-016-0988-z.
- Murphy D, Mattey D, Hutchinson D. Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se. PLoS ONE. 2017;12:e0180655. doi: 10.1371/journal.pone.0180655.
- Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 2010;22:307–315. doi: 10.1097/BOR.0b013e3283369cb8.
- Smith CI, et al. The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays. 2001;23:436–446. doi: 10.1002/bies.1062.
- Bao Y, et al. Tyrosine kinase Btk is required for NK cell activation. J. Biol. Chem. 2012;287:23769–23778. doi: 10.1074/jbc.M112.372425.
- Xia S, Liu X, Cao X, Xu S. T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell. Mol. Immunol. 2019 doi: 10.1038/s41423-019-0270-9.
- Weber ANR, et al. Bruton's tyrosine kinase: An emerging key player in innate immunity. Front. Immunol. 2017;8:1454–1454. doi: 10.3389/fimmu.2017.01454.
- Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Am. J. Hum. Genet. 1998;62:1034–1043. doi: 10.1086/301828.
- Desiderio S. Role of Btk in B cell development and signaling. Curr. Opin. Immunol. 1997;9:534–540. doi: 10.1016/S0952-7915(97)80107-0.
- de Porto AP, et al. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia. Mol. Med. 2019;25:3–3. doi: 10.1186/s10020-018-0069-7.
- Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. 2010;107:13075–13080. doi: 10.1073/pnas.1004594107.
- Cohen S, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: A randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72:1435–1446. doi: 10.1002/art.41275.
- Schafer PH, et al. Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: Results from a mechanistic study. Rheumatol. Ther. 2020;7:101–119. doi: 10.1007/s40744-019-00182-7.
- Kim Y-Y, et al. HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res. Ther. 2017;19:211. doi: 10.1186/s13075-017-1402-1.
- Middendorp S, Dingjan GM, Maas A, Dahlenborg K, Hendriks RW. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J. Immunol. 2003;171:5988–5996. doi: 10.4049/jimmunol.171.11.5988.
- Wu J, Zhu Z, Yu Q, Ding C. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: Phase I to II clinical trials. Expert Opin. Investig. Drugs. 2019;28:1113–1123. doi: 10.1080/13543784.2019.1692812.
- Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch. Immunol. Ther. Exp. 2008;56:77–83. doi: 10.1007/s00005-008-0014-5.
- Cyster JG, Allen CDC. B cell responses: Cell interaction dynamics and decisions. Cell. 2019;177:524–540. doi: 10.1016/j.cell.2019.03.016.
- Becerra E, De La Torre I, Leandro MJ, Cambridge G. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: Expression of B cell-activating factor-binding receptors on B cell subsets. Clin. Exp. Immunol. 2017;190:372–383. doi: 10.1111/cei.13024.
- Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat. Rev. Immunol. 2017;17:421–436. doi: 10.1038/nri.2017.24.
- Hu Y, Yang Y, Luo B. Evaluation of destruction in a collagen-induced arthritis rat model: Bony spur formation. Exp. Ther. Med. 2017;14:2563–2567. doi: 10.3892/etm.2017.4817.
- Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers. Biomed. Res. Int. 2014;2014:681678. doi: 10.1155/2014/681678.
- Yap HY, et al. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells. 2018 doi: 10.3390/cells7100161.
- Lon HK, et al. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm. Res. 2011;28:1622–1630. doi: 10.1007/s11095-011-0396-7.
- Haselmayer P, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J. Immunol. 2019;202:2888–2906. doi: 10.4049/jimmunol.1800583.
- Evans EK, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J. Pharmacol. Exp. Ther. 2013;346:219–228. doi: 10.1124/jpet.113.203489.
- Yu H, et al. Homogeneous BTK occupancy assay for pharmacodynamic assessment of tirabrutinib (GS-4059/ONO-4059) target engagement. SLAS Discov. 2018;23:919–929. doi: 10.1177/2472555218786165.
- Daryaee F, et al. A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy. Chem. Sci. 2017;8:3434–3443. doi: 10.1039/c6sc03306g.
- Grimstein M, et al. Physiologically based pharmacokinetic modeling in regulatory science: An update from the US food and drug Administration’s office of clinical pharmacology. J. Pharmac. Sci. 2019;108:21–25. doi: 10.1016/j.xphs.2018.10.033.
Source: PubMed